Premium
Pharmacokinetics of dietary equol in ovariectomized rats
Author(s) -
Legette LeeCole L,
Prasain Jeevan,
Arabshahi Alireza,
Barnes Stephen,
Weaver Connie M
Publication year - 2010
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.24.1_supplement.540.4
Subject(s) - equol , daidzein , pharmacokinetics , ovariectomized rat , metabolite , isoflavones , chemistry , population , genistein , endocrinology , medicine , pharmacology , biochemistry , hormone , environmental health
Recent findings indicate that soy isoflavones and their metabolites may play a major role in mitigating post‐menopausal bone loss. Equol, a metabolite of soy isoflavone daidzein produced by intestinal bacteria, has shown some potential but only 30–50% of US population is capable of converting dietary daidzein to equol. There is limited data on the pharmacokinetics of dietary equol and its metabolites. This study was conducted to assess the levels of equol and its conjugates in plasma for a 24h period resulting from oral administration of dietary equol in ovariectomized Sprague Dawley rats. Plasma samples were analyzed for using liquid chromatography‐tandem mass spectrometry. Although the majority of equol metabolites present were glucronidated conjugates (≥99%), there were low levels of sulfated conjugates present, specifically equol monosulfate. Pharmacokinetic parameters for equol monosulfate were: C max (21±7 nmol/L), T max (2.8±2h), AUC 0‐t (237±79 nmol h/L), AUC 0‐inf (600±390 nmol h/L), T 1/2 (32±24h). Pharmacokinetic parameters for glucronidated equol were: C max (10.5±2.9μmol/L), T max (0.88±0.75h), AUC 0‐t (11±14 μmol h/L), AUC 0‐inf (179±14 μmol h/L), and T 1/2 (16±3h). Grant Funding Source : NIH